Previous 10 | Next 10 |
Alcon innovations featured in approximately 180 abstracts across cataract, glaucoma, refractive, visualization and ocular health 1 New data demonstrates comparable range of vision and intermediate visual acuity between Clareon monofocal IOL and TECNIS Eyhance* monofocal IOL 2 ...
Alcon welcomes its shareholders to its first in-person AGM In addition to the regular agenda items, Alcon Board of Directors proposes to amend the Articles of Incorporation to conform to recent Swiss corporate law reform Proposed dividend of CHF 0.21 cash per share ...
Silver Anthem Award Recognizes The Lens as Best Special Workforce Initiative: Health Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that its interactive compliance training video experience, The Lens, has been named Best Special Workf...
Alcon (SIX/NYSE: ALC), the global leader in eye care, will host its 2023 Capital Markets Day on March 30, 2023 beginning at 8:00 a.m. CT. A live webcast of the event will be available at https://investor.alcon.com/news-and-events/events-and-presentations/default.aspx . About Alcon...
TOTAL30 for Astigmatism, the first and only reusable Water Gradient toric lens, is now available nationwide in the U.S. Alcon highlights the expansion of its toric lens portfolio with latest innovations, including DAILIES TOTAL1 for Astigmatism and PRECISION1 for Astigmatism, to be showcased ...
Alcon Inc. (ALC) Q4 2022 Earnings Conference Call February 28, 2023 08:00 ET Company Participants Dan Cravens - Vice President & Global Head of Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Cal...
Summary Brent Saunders led Bausch + Lomb Corporation when it was sold to Valeant Pharmaceuticals. He later led and sold competitor Allergan to AbbVie. Brent Saunders likely signed on as CEO with the expectation of operating Bausch + Lomb Corporation as a fully standalone company. ...
Alcon press release ( NYSE: ALC ): Q4 Non-GAAP EPS of $0.42 in-line. Revenue of $2.16B (+1.4% Y/Y) in-line. Surgical net sales, which include implantables, consumables and equipment/other, were $1.3 billion, an increase of 1% on a reported basis Implantables net sales of $...
Fourth quarter 2022 sales of $2.2 billion, up 1%, or 7% constant currency (1) (cc) Full year 2022 sales of $8.7 billion, up 5%, or up 11% cc Full year 2022 diluted EPS of $0.68, down 11%, or up 37% cc; core diluted EPS (2) of $2.24 up 4%, or 23% cc 2023 outlook ref...
Eye care company Alcon ( NYSE: ALC ) has reached a settlement with J&J Surgical Vision on its pending legal proceedings related to femtosecond laser assisted cataract surgery devices. The parties have exchanged cross-licenses of certain intellectual property and other mutually...
News, Short Squeeze, Breakout and More Instantly...
Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovation Alcon to immediately begin collecting real-world user experience in the U.S. prior ...
2024-06-09 17:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of Alcon Inc. (NYSE: ALC) traded at a new 52-week high today and are currently trading at $91.69. So far today, approximately 136.09k shares have been exchanged, as compared to an average 30-day volume of 907.93k shares. Alcon Inc., an eye care company, researches, develops, manufactur...